Weindler Jasmin, Ali Muhammad, Udovicich Cristian, Hofman Michael S, Siva Shankar
Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
BMJ Oncol. 2025 Aug 17;4(1):e000645. doi: 10.1136/bmjonc-2024-000645. eCollection 2025.
Conventional diagnostic strategies for imaging patients with renal cell carcinoma (RCC) have predominantly relied on ultrasonography, CT and MRI. However, a paradigm shift is underway with the emergence of several new radiotracers for molecular imaging. Carbonic anhydrase IX (CA-IX) imaging and sestamibi imaging can assist with identifying malignant renal tumours, whereas fluorodeoxyglucose, prostate-specific membrane antigen and CA-IX tracers can give guidance for diagnosis and staging of RCC. These tracers can assist in enabling better decision-making by minimising overtreatment of renal masses with biopsy, better selecting patients for curative-intented management and optimising treatment for patients with oligo-metastatic disease, among other emerging indications. However, none of them is yet recommended as a standard clinical diagnostic procedure. In this review, we investigate the latest developments in molecular imaging for detecting and staging RCC, aiming to advance precision diagnosis and improve patient outcomes.
肾细胞癌（RCC）患者的传统影像学诊断策略主要依赖于超声、CT和MRI。然而，随着几种用于分子成像的新型放射性示踪剂的出现，正在发生范式转变。碳酸酐酶IX（CA-IX）成像和心肌灌注显像剂成像可辅助识别恶性肾肿瘤，而氟脱氧葡萄糖、前列腺特异性膜抗原和CA-IX示踪剂可为RCC的诊断和分期提供指导。这些示踪剂有助于通过尽量减少肾肿块活检的过度治疗、更好地选择适合根治性治疗的患者以及优化寡转移性疾病患者的治疗等其他新出现的适应症，来做出更好的决策。然而，目前尚无一种被推荐作为标准的临床诊断程序。在本综述中，我们研究了用于检测和分期RCC的分子成像的最新进展，旨在推进精准诊断并改善患者预后。
